

**Anti-IL-1b Reference Antibody (gevokizumab)
Recombinant Antibody
Catalog # APR10283****Specification**

Anti-IL-1b Reference Antibody (gevokizumab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P01584
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	145.12 KDa

Anti-IL-1b Reference Antibody (gevokizumab) - Additional Information**Target/Specificity**
IL-1b**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in 100mM Pro-Ac, 20mM Arg, pH5.0, without preservative.This antibody is purified through a protein A column.**Anti-IL-1b Reference Antibody (gevokizumab) - Protein Information****Name** IL1B ([HGNC:5992](#))**Synonyms** IL1F2**Function**
Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:<a

[10653850](http://www.uniprot.org/citations/10653850)). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:[12794819](http://www.uniprot.org/citations/12794819)). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:[33377178](http://www.uniprot.org/citations/33377178), PubMed:[33883744](http://www.uniprot.org/citations/33883744)). Acts as a sensor of *S.pyogenes* infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:[28331908](http://www.uniprot.org/citations/28331908)).

Cellular Location

Cytoplasm, cytosol. Secreted. Lysosome Secreted, extracellular exosome {ECO:0000250|UniProtKB:P10749} Note=The precursor is cytosolic (PubMed:15192144). In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome or bacterial flagellin for NLRC4 inflammasome, cleaved and secreted (PubMed:24201029, PubMed:33377178, PubMed:33883744). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744). In contrast, the precursor form is not released, due to the presence of an acidic region that is proteolytically removed by CASP1 during maturation (PubMed:33883744). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059)

Tissue Location


Expressed in activated monocytes/macrophages (at protein level).


Anti-IL-1b Reference Antibody (gevokizumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-IL-1b Reference Antibody (gevokizumab) - Images





Anti-IL-1b Reference Antibody (gevokizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-1b Reference Antibody (gevokizumab) is more than 98.81% ,determined by SEC-HPLC.